MPN: Next Questions: Potential New Targets for MPN beside JAK2

The discovery of activating JAK2 mutations changed the landscape of MPN treatment dramatically, quickly prompting the development of small molecule inhibitors of JAK2. First-generation JAK inhibitors are ATP-competitive antagonists of the JAK kinase domain and each inhibits the activity of one or more JAK isoforms to different degrees. Ruxolitinib, a dual JAK1/2 inhibitor, was the first of its class to be approved for treatment of primary myelofibrosis (PMF) and post-PV/ET MF. Treatment with ruxolitinib has been shown to reduce spleen size and alleviate systemic symptoms of MF1, although the myelosuppressive effects of ruxolitinib, particularly anemia, are problematic for MF patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ann Mullally Source Type: research